Recurrent Osteosarcoma Clinical Trial
Official title:
Retrospective Study of Genetic Risk Factors for Osteosarcoma
This research trial studies blood samples from patients with osteosarcoma. Studying the genes found in samples of blood from patients with osteosarcoma may help doctors identify biomarkers related to the disease.
PRIMARY OBJECTIVE:
I. Conduct a large-scale candidate gene association study in osteosarcoma (OS) using cases
from the national Children's Oncology Group (COG) OS biology study (P9851 and successor
study AOST06B1).
SECONDARY OBJECTIVES:
I. Conduct a genome-wide association study (GWAS) of OS. II. Fine-map genomic regions
associated with OS to identify putative functional loci.
III. Conduct whole-exome sequencing of germline OS deoxyribonucleic acid (DNA) samples.
IV. Investigate the functional implications of promising genetic variants associated with
OS.
OUTLINE:
Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and
haplotypes to examine genetic variation, gene-gene interactions, and the population
structure.
;
Observational Model: Case Control, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT05515068 -
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
|
||
Completed |
NCT00093821 -
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03213678 -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT04668300 -
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
|
Phase 2 | |
Completed |
NCT02470091 -
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
|
Phase 2 | |
Completed |
NCT01807052 -
Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas
|
N/A | |
Completed |
NCT01016015 -
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT03698994 -
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Not yet recruiting |
NCT03205644 -
VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04320888 -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Completed |
NCT00030667 -
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
|
Phase 2 |